Recombinant Human EBAG9 Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-1674

Recombinant Human EBAG9 Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-1674
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag His
Host Species Human
Accession O00559
Synonym EB9, PDAF
Background RCAS1, also known as EBAG9, is a tumor-associated antigen that is expressed at high frequency in a variety of cancers. RCAS1 gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor which binds to the estrogen-responsive element (ERE) found in the 5'-flanking region of RCAS1 gene. Two transcript variants differing in the 5' UTR, but encoding the same protein, have been identified for RCAS1 gene. EBAG9 may participate in suppression of cell proliferation and induces apoptotic cell death through activation of interleukin-1-beta converting enzyme (ICE)-like proteases.
Description A DNA sequence encoding the mature form of human EBAG9 (O00559) (Arg28-Ser213) was expressed with a His tag at the N-terminus.
Source E.coli
Predicted N Terminal His
AA Sequence Arg28-Ser213
Molecular Weight The recombinant human EBAG9 consists of 201 a.a. and predicts a molecular mass of 23 KDa. It migrates as an approximately 33 KDa band in SDS-PAGE under reducing conditions.
Purity >90% as determined by SDS-PAGE
Endotoxin Please contact us for more information.
Bioactivity Please contact us for detailed information
Formulation Lyophilized from sterile PBS, pH 7.4..
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function May participate in suppression of cell proliferation and induces apoptotic cell death through activation of interleukin-1-beta converting enzyme (ICE)-like proteases.
Subcellular Location Golgi apparatus membrane; Single-pass type III membrane protein. Note=According to PubMed:10426319, it also exists as a soluble form which has the same biological activities. The existence of such soluble form is however uncertain.
Database References
Tissue Specificity Widely expressed. Expressed in ovary, testis, prostate, thymus, muscle and heart, but not in small intestine, colon, lymph nodes, or peripherical blood lymphocytes. The protein is not detected in any of the above organs.

Gene Functions References

  1. Data suggest that joint detection of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) and carcinoembryonic antigen (CEA) can improve the diagnostic sensitivity and specificity. PMID: 26438059
  2. RCAS1 seems to be involved in creating tumor-induced inflammation in the tumor and its microenvironment PMID: 25773455
  3. High EBAG9 expression is associated with malignant pleural effusion in patients with lung cancer. PMID: 24720371
  4. Findings suggest that the histological effect of increased RCAS1 expression depends on its cellular source and that RCAS1 expression itself is a component of various signaling pathways in urothelial bladder cancer cells. PMID: 25674852
  5. suggests that RCAS1 has an apoptotic function via membranous/soluble expression pattern in OSCC cells. RCAS1 may thus affect tumor escape from immune surveillance in OSCC by inducing apoptosis PMID: 24885040
  6. RCAS1 could be a useful immunohistochemical biomarker, indicating not only tumor aggressiveness but also a poorer prognosis for patients with NSCLC. PMID: 24815841
  7. High EBAG9 expression is associated with tamoxifen resistance in breast cancer. PMID: 24119785
  8. sRCAS1 levels could have a clinical value for the diagnosis and management of lung cancer and could be used as a new tumor marker of lung cancer. PMID: 23881387
  9. RCAS1 may play an important role in the phenomenon of tumor escape from host immunological surveillance and in creating the immune tolerance for the tumor cells, as well as in the tumor microenvironment. PMID: 23164108
  10. The membrane molecule RCAS1 induces immune cell apoptosis via the RCAS1-RCAS1R pathway. PMID: 23563217
  11. The intensity of the suppressive profile of the cervical cancer microenvironment indicated by the presence of both RCAS1 and B7H4 on the front of the tumor and in the macrophages and fibroblasts infiltrating the cancer stroma PMID: 22530960
  12. RCAS1 protein may participate in thyroid neoplastic transformation and could be considered as a useful biomarker to improve diagnostic scrutiny. PMID: 22460085
  13. The immunoreactivity of RCAS1 on the cells present in the ovarian cancer microenvironment, was analysed. PMID: 21845402
  14. Data suggest that RCAS1 may be involved in the early stages of tumor progression in mobile tongue squamous cell carcinoma. PMID: 21804460
  15. We observed a statistically significant increase in the RCAS1-positive macrophage infiltration within the microenvironment of the molar lesions in patients with partial hydatidiform mole in comparison with those who exhibited complete hydatidiform mole. PMID: 20645939
  16. analyzed RCAS-1 as a biomarker in the serum of patients with head and neck squamous cell carcinoma PMID: 20571277
  17. EBAG9 acts as a negative regulator of a COPI-dependent ER-to-Golgi transport pathway in epithelial cells and shows pathogenetic principle in which interference with intracellular membrane trafficking results in the emergence of a tumor-associated glycome PMID: 20570965
  18. RCAS1 can be used as a serum tumor marker for diagnosis of pancreatic cancer. PMID: 19957811
  19. the RCAS1 putative receptor-expressing chronic myelogenous leukemia cell line K562 was co-cultured with SiSo, MCF-7, or soluble RCAS1 to follow RCAS1 secretion in apoptosis initiation PMID: 20079734
  20. NASP and RCAS1 proteins were more frequently expressed in ovarian cancer tissues than with normal ovarian tissue and serous cystadenomas and MRE11 was less frequently expressed PMID: 20164540
  21. Overrepresentation of EBAG9 may play a specific role in early stages of breast carcinogenesis. PMID: 11705872
  22. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker PMID: 11992411
  23. RCAS1 is associated with ductal breast cancer progression PMID: 12054692
  24. modulates surface expression of tumor-associated, normally cryptic O-linked glycan structures and contributes indirectly to the antigenicity of tumor cells PMID: 12672804
  25. RCAS1 expressed on macrophages may play an important role in the induction of activated T-cell apoptosis in cases of HNL PMID: 12774924
  26. Overexpression of EBAG9 is correlated with advanced pathologic stages of prostate cancer PMID: 12845666
  27. RCAS1 may have role endometrial cancer invasiveness; overexpression associated with significantly poorer prognosis PMID: 12888828
  28. RCAS1 gene or protein expression may not correlate with tumor progression in esophageal squamous cell carcinoma PMID: 14534714
  29. The mean survival of patients who had primary hepatocellular carcinoma with high RCAS1 protein expression was significantly longer than that of patients with low expression. PMID: 14981953
  30. wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer PMID: 15164121
  31. RCAS1 expression might be associated with progression of oral squamous cell carcinoma PMID: 15254686
  32. Serum RCAS1 appears to be valuable as a diagnostic index for biliary carcinomas, as well as for evaluating the progression of cancers during therapy. PMID: 15460847
  33. EBAG9 and Snapin have roles in controlling exocytosis processes PMID: 15635093
  34. Macrophages may negatively regulate erythropoiesis at least in part through the production of RCAS1 molecules. PMID: 15813909
  35. EBAG9 is a crucial regulator of tumor progression and a potential prognostic marker for RCC. PMID: 15867365
  36. the estrogen-inducible EBAG9 gene-product and the 22-1-1 defined antigen are structurally and functionally separate antigens PMID: 15904507
  37. RCAS1 expression is informative for the follow-up of malignant mesothelioma patients and sRCAS1 in pleural fluid may be useful for the diagnosis of malignant mesothelioma. PMID: 16012715
  38. RCAS1 may contribute to acquisition of malignant uterine cervical phenotypic characteristics including invasion, metastasis, and tumor growth via connective tissue remodeling. PMID: 16112176
  39. RCAS1 and CAP may play a role in the downregulation of the maternal immune response during pregnancy and may participate in the initiation of the labor PMID: 16113565
  40. distribution of RCAS1 expression in normal female genital organs; significant positive correlation between age and RCAS1 expression; RCAS1 may affect metaplastic processes and tumor progression PMID: 16175077
  41. expression of RCAS1 is correlated with recurrence not only in carcinomas, but also in mesenchymal tumors PMID: 16211275
  42. metastatic lymph nodes from bile duct, gastric, colon and pancreatic cancer were investigated for RCAS1 expression PMID: 16273616
  43. RCAS1 expression in gliomas may play roles in tumor progression and tumor immune escape. PMID: 16595162
  44. The expression of RCAS1 by endometrial cells may favor the persistence of these cells in ectopic localization both in scar following cesarean section and in ovarian endometriosis. PMID: 16907986
  45. Significantly higher RCAS1 expression was noticed in tumor in comparison to stroma in patients with the presence of lymph nodes metastases. No such difference was observed in patients without the metastases. PMID: 17187007
  46. RCAS1 expression was simultaneous to the infiltration of activated immunological cells of tumor environment as well as decidua. The activity of immunological cells was selectively suppressed. PMID: 17187008
  47. High-level expression of RCAS1 is involved in the malignant transformation of endometrium, and RCAS1 coexpression with ER-alpha may be associated with development and metastasis of endometrial carcinoma PMID: 17466050
  48. The expression of RCAS1 in cervical cancer is significantly increased, and has correlation with malignant degree of cervical carcinoma. Some RCAS1-positive cervical cancer tissues are infected by HPV16. PMID: 17562271
  49. possible role of the RCAS1 protein in the development of pre-eclampsia through an immunological pathway. PMID: 17604121
  50. the drop of the RCAS1 level, which could be a result of an insufficiency of the compensatory immune response mechanisms in tubal mucosa (although these mechanisms are simultaneously preserved in endometrium), leads to tubal perforation. PMID: 17717421


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed